08:27 EST Evommune (EVMN) jumps 67% to $28.13 after atopic dermatitis data
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EVMN:
- Evommune reports EVO301 trial met primary endpoint
- Evommune management to meet with Oppenheimer
- 3 ‘Strong Buy’ Stocks to Buy Now, According to Top Analysts
- Evommune initiated with an Outperform at Oppenheimer
- Evommune: Buy Rating Driven by Upcoming Phase II Readouts and Broad Inflammatory Disease Pipeline Potential